Investing, Directing,
Supporting, Expanding.
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
The Idealistic Genius
Duggan Investments is a hands-on, active investment company, headed by Robert Duggan, who has many decades of success and experience.
An example: Under Bob’s guidance, Pharmacyclics' stock price increased from $0.57 a share in Feb 2009, to $261.25 a share in May 2015. Pharmacyclics and its "miracle drug" IMBRUVICA® were acquired by AbbVie for $21 billion in May 2015. As of today, IMBRUVICA® continues its dramatic growth and success, with use in widening indications.
Duggan Investments’ current projects are focused on cutting-edge biosciences. These include groundbreaking developments in cancer treatment, anti-microbial advancements, anti-aging technologies, and stem cell research.
Selective. Results-driven. Successful. Dedicated to making a difference for the betterment of all involved. That’s Duggan Investments.
Current Projects
Duggan Investments focuses on groundbreaking bioscience companies. With cancer treatment, anti-microbial treatment, anti-aging, and stem cell research, our involvement with these cutting-edge technologies is to improve life for all.
Revolutionizing Cancer Treatment with Ivonescimab
Summit Therapeutics
Revolutionizing Healthcare with nsPFA™ Technology
Pulse Biosciences
Past Projects
Robotic-assisted Surgery (RAS)
Intuitive Surgical
Greater Precision & Dexterity Than Human Surgeons
Computer Motion
Revolutionizing Healthcare with nsPFA™ Technology
Pharmacyclics
“The conditions of life can and need to improve for the betterment of all involved.”
Bob Duggan – Founder
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
